Phase 1b/2a safety and tolerability study of bemcentinib (BEM) with pembrolizumab/carboplatin/pemetrexed in first line (1L) advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without/with a STK11 mutation.

Authors

Rajwanth Veluswamy

Icahn School of Medicine at Mount Sinai, New York, NY

Rajwanth Veluswamy , Sheena Bhalla , Ranee Mehra , Marina Chiara Garassino , Oleg Gligich , Cristina Oliva , Claudia Gorcea-Carson , Nigel William McCracken

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab.

First Author: Martin Reck

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A phase II randomized, open-labelled, multicenter study of safety and efficacy of combination brigatinib and carboplatin-pemetrexed therapy or brigatinib monotherapy as first-line treatment in patients with advanced ALK-positive non–small cell lung cancer (IFCT-2101 MASTERPROTOCOL ALK).

First Author: Michaël Duruisseaux

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

The potential cost-effectiveness of first-line immunotherapy + chemotherapy for advanced non-squamous non-small cell lung cancer (NSCLC).

First Author: Joshua A. Roth

insert_chart_outlined

Poster

2016 ASCO Annual Meeting

bookmark_border

Phase 3 study of first-line crizotinib vs pemetrexed−cisplatin/carboplatin (PCC) in East Asian patients (pts) with ALK+ advanced non-squamous non-small cell lung cancer (NSCLC).

First Author: Shun Lu